Development of Radiological/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices

SOL #: BAA-75N93026R00004Solicitation

Overview

Buyer

Health And Human Services
National Institutes Of Health
NATIONAL INSTITUTES OF HEALTH NIAID
BETHESDA, MD, 20892, United States

Place of Performance

Bethesda, MD

NAICS

Research and Development in the Physical (541715)

PSC

Health R&D Services; Health Care Services; Applied Research (AN12)

Set Aside

No set aside specified

Timeline

1
Posted
Jan 15, 2026
2
Last Updated
Mar 13, 2026
3
Submission Deadline
May 4, 2026, 7:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The National Institutes of Health (NIH) NIAID, under the Department of Health and Human Services, has issued Solicitation BAA-75N93026R00004 for the Development of Radiological/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices. This opportunity seeks to advance either MCMs to mitigate/treat radiation injuries or biodosimetry biomarkers/devices for public health emergency triage and treatment. This is a Cost-Reimbursement Completion contract, not set-aside for small business, with proposals due by May 4, 2026.

Scope of Work

Proposals must address one of two primary goals:

  1. Development of MCMs: Focus on mitigating and/or treating normal tissue injuries from ionizing radiation, particularly those efficacious 24 hours or later post-exposure. Lead MCM candidates must demonstrate clinical relevance, safety, and a defined Target Product Profile.
  2. Advancement of Biodosimetry Devices: Develop biomarkers or devices to assess radiation exposure levels and tissue injuries. Point-of-care devices should distinguish exposed/unexposed populations with a sample-to-answer time of 30 minutes or less. Definitive care devices must measure absorbed radiation exposure and tissue injury within 7 days post-exposure. All proposals must include plans for translational research and development, and potentially Investigational New Drug (IND) or Investigational Use Only (IUO) applications.

Contract & Timeline

  • Contract Type: Multiple-year Cost-Reimbursement Completion contract.
  • Period of Performance: A base period (TBD) with two (2) option periods.
  • Estimated Funding: Anticipated 1-2 awards with a total planned funding of $12 million over three years.
  • Set-Aside: Not set-aside for small business.
  • NAICS Code: 541715 (Small Business Size Standard: 1,000 employees).
  • Proposal Submission Deadline: May 4, 2026, by 3:00 PM Eastern Time.
  • Questions Deadline: March 3, 2026.
  • Published Date: February 10, 2026.

Evaluation

Proposals will be evaluated based on the following criteria:

  • Technical (50%)
  • Scientific and Technical Personnel (20%)
  • Project Management (15%)
  • Organizational Facilities, Equipment, and Other Resources (15%)

Additional Notes

Offerors must be registered in the System for Award Management (SAM). Key personnel changes require Contracting Officer approval. Specific clauses regarding human subjects, animal welfare, data management, and ICT accessibility are incorporated. The place of performance is Bethesda, MD. Primary contact for inquiries is Lisa Anglin (lisa.anglin@nih.gov, 240-292-4402).

People

Points of Contact

Robert CornoSECONDARY

Files

Files

Download

Versions

Version 3
Solicitation
Posted: Mar 13, 2026
View
Version 2Viewing
Solicitation
Posted: Feb 10, 2026
Version 1
Pre-Solicitation
Posted: Jan 15, 2026
View
Development of Radiological/Nuclear Medical Countermeasures (MCMs) And Biodosimetry Devices | GovScope